Donor lymphocyte infusion, also called buffy coat infusion, is a form of adoptive immunotherapy used to treat relapse of blood cancers after a hematopoietic stem cell transplant. White blood cells are collected from the original stem cell donor by apheresis and infused into the transplant recipient, where the donor's T cells attack and control residual cancer cells through a mechanism known as the graft versus tumor effect. Before this therapy was developed, patients who relapsed after a transplant had few curative options besides attempting a second, riskier transplant.
Facts
Donor lymphocyte infusion
Filter Results1 entry
FAQs
Does donor lymphocyte infusion always work after a relapse?
Sustained remission is reported in 20 to 80 percent of patients depending on the disease and the amount of remaining disease.
No. A review in the medical literature describes the treatment as an established therapy for relapsed disease or expected relapse, and reports that sustained remission can be seen in 20 to 80 percent of patients treated with it. How well it works depends on the underlying disease and on how many targeted cells remain. This is general information, not medical advice.
Connections
Treats
Source Donor lymphocyte infusion (Wikipedia)
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundation
2. Donor lymphocyte infusion (Wikipedia)
- First used in 1990 at LMU Klinikum in Munich, Germany
https://en.wikipedia.org/wiki/Donor_lymphocyte_infusion, lead section
Donor lymphocyte (or leukocyte) infusion (DLI) or buffy coat infusion is a form of adoptive immunotherapy used to treat relapses after hematopoietic stem cell transplantation for several types of blood cancer.
In Group: Blood Transfusion and Blood Components, Lead section
Donor lymphocyte (or leukocyte) infusion (DLI) or buffy coat infusion is a form of adoptive immunotherapy used to treat relapses after hematopoietic stem cell transplantation
Treats: Cancer, Lead: treats Cancer
Donor lymphocyte (or leukocyte) infusion (DLI) or buffy coat infusion is a form of adoptive immunotherapy used to treat relapses after hematopoietic stem cell transplantation for several types of blood cancer.
View the SourceReader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.
View At A Past Year
Choose a year to see this entry's facts and connections as the atlas records them at that moment: what it held then, what it held instead, and what it had not yet adopted. Choose Present for the current record.